Cadonilimab Receives Regulatory Approval from China's NMPA for First-Line Treatment of Advanced Cervical Cancer, Reports Akeso Inc

Reuters

06-16

Cadonilimab Receives Regulatory Approval from China's NMPA for First-Line Treatment of Advanced Cervical Cancer, Reports Akeso Inc

Akeso Inc. has announced a significant regulatory approval for their innovative treatment, cadonilimab. The China National Medical Products Administration (NMPA) has approved the use of cadonilimab as a first-line treatment for advanced, recurrent, or metastatic cervical cancer as of May 2025. This approval marks an important milestone for Akeso, as cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody, has shown significant improvements in progression-free survival and overall survival in various patient subgroups. This development highlights the ongoing impact of cadonilimab in transforming the treatment standards for advanced cervical cancer and underscores its potential global health benefits for women.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN10670) on June 16, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2543610732"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2543610732\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2543610732?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-16 09:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2543610732","market":"nz","top_or_hot":-1,"title":"Cadonilimab Receives Regulatory Approval from China's NMPA for First-Line Treatment of Advanced Cervical Cancer, Reports Akeso Inc","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cadonilimab Receives Regulatory Approval from China's NMPA for First-Line Treatment of Advanced Cervical Cancer, Reports Akeso Inc\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Akeso Inc. has announced a significant regulatory approval for their innovative treatment, cadonilimab. The China National Medical Products Administration (NMPA) has approved the use of cadonilimab as a first-line treatment for advanced, recurrent, or metastatic cervical cancer as of May 2025. This approval marks an important milestone for Akeso, as cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody, has shown significant improvements in progression-free survival and overall survival in various patient subgroups. This development highlights the ongoing impact of cadonilimab in transforming the treatment standards for advanced cervical cancer and underscores its potential global health benefits for women.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN10670) on June 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cadonilimab Receives Regulatory Approval from China's NMPA for First-Line Treatment of Advanced Cervical Cancer, Reports Akeso Inc</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCadonilimab Receives Regulatory Approval from China's NMPA for First-Line Treatment of Advanced Cervical Cancer, Reports Akeso Inc\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-16 09:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cadonilimab Receives Regulatory Approval from China's NMPA for First-Line Treatment of Advanced Cervical Cancer, Reports Akeso Inc\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Akeso Inc. has announced a significant regulatory approval for their innovative treatment, cadonilimab. The China National Medical Products Administration (NMPA) has approved the use of cadonilimab as a first-line treatment for advanced, recurrent, or metastatic cervical cancer as of May 2025. This approval marks an important milestone for Akeso, as cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody, has shown significant improvements in progression-free survival and overall survival in various patient subgroups. This development highlights the ongoing impact of cadonilimab in transforming the treatment standards for advanced cervical cancer and underscores its potential global health benefits for women.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN10670) on June 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250616:nNDL83jy4r:1","article_id":"2543610732","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2543610732","pubTimestamp":1750037143,"columns":[{"name":"财报速递","id":26,"label_key":"express"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cadonilimab Receives Regulatory Approval from China's NMPA for First-Line Treatment of Advanced Cervical Cancer, Reports Akeso Inc. Akeso Inc. has announced a significant regulatory approval for their innovative treatment, cadonilimab. The China National Medical Products Administration  has approved the use of cadonilimab as a first-line treatment for advanced, recurrent, or metastatic cervical cancer as of May 2025. This approval marks an important milestone for Akeso, as cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody, has shown significant improvements in progression-free survival and overall survival in various patient subgroups. This development highlights the ongoing impact of cadonilimab in transforming the treatment standards for advanced cervical cancer and underscores its potential global health benefits for women.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1574":"生物医药B类股","LU1720050803.USD":"安联全方位中国股票基金","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","09926":"康方生物","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","BK1161":"生物科技","LU0348783233.USD":"安联东方收入型 CI A Dis美元","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC"},"translate_title":"康方生物报道，卡多尼单抗获得中国国家药监局监管批准，用于晚期宫颈癌的一线治疗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":0.9},"content_text":"Cadonilimab Receives Regulatory Approval from China's NMPA for First-Line Treatment of Advanced Cervical Cancer, Reports Akeso Inc\n    \n\n        Akeso Inc. has announced a significant regulatory approval for their innovative treatment, cadonilimab. The China National Medical Products Administration (NMPA) has approved the use of cadonilimab as a first-line treatment for advanced, recurrent, or metastatic cervical cancer as of May 2025. This approval marks an important milestone for Akeso, as cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody, has shown significant improvements in progression-free survival and overall survival in various patient subgroups. This development highlights the ongoing impact of cadonilimab in transforming the treatment standards for advanced cervical cancer and underscores its potential global health benefits for women.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN10670) on June 16, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,express","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}